Detecting Ovarian Cancer Earlier with New MIT Tissue Sampling Device

Ovarian cancer is one of the deadliest forms of cancer. Although the five-year survival rate can be as high as 90% when caught in early stages of the disease, that survival rate drops dramatically when the cancer is identified at stage 3 or 4.

Unfortunately, diagnosing ovarian cancer at any stage is challenging. Researchers at Massachusetts Institute of Technology (MIT) and Johns Hopkins University are working diligently to address this issue, as reported in a new paper published in Device, with the goal of improving the ability to both detect ovarian cancer early and to utilize a patient’s own cells to develop treatments.